{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:24:41Z","timestamp":1783977881827,"version":"3.55.0"},"reference-count":16,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2024,5,28]]},"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1136\/ejhpharm-2024-004124","type":"journal-article","created":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T13:20:29Z","timestamp":1717680029000},"page":"534-538","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Inpatient case characteristics of SGLT2 inhibitor-associated diabetic ketoacidosis: a retrospective study"],"prefix":"10.1136","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4991-7190","authenticated-orcid":false,"given":"Zhongpei","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of QianNan, Duyun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hefeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"2025102402100662000_32.6.534.1","first-page":"315","article-title":"Guidelines for the prevention and treatment of type 2 diabetes mellitus in China","volume":"13","year":"2021","journal-title":"Chinese J Diabetes"},{"key":"2025102402100662000_32.6.534.2","doi-asserted-by":"crossref","DOI":"10.7326\/ACPJ202012150-070","article-title":"In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs DPP-4 inhibitors","volume":"173","author":"Liakos","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025102402100662000_32.6.534.3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2337\/dc21-2177","article-title":"Comparative safety of sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis.diabetes care","volume":"45","author":"Dawwas","year":"2022","journal-title":"Diabetes Care"},{"key":"2025102402100662000_32.6.534.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2025102402100662000_32.6.534.5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajem.2021.02.015","article-title":"Euglycemic diabetic ketoacidosis: etiologies, evaluation, and management","volume":"44","author":"Long","year":"2021","journal-title":"Am J Emerg Med"},{"key":"2025102402100662000_32.6.534.6","first-page":"330","article-title":"Research progress on the mechanism of sodium-glucose cotransporter protein 2 inhibitor triggering diabetic ketoacidosis","volume":"38","author":"Min","year":"2018","journal-title":"Chinese J Hosp Pharm"},{"key":"2025102402100662000_32.6.534.7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025102402100662000_32.6.534.8","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1481"},{"key":"2025102402100662000_32.6.534.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4301-8"},{"key":"2025102402100662000_32.6.534.10","doi-asserted-by":"crossref","first-page":"110236","DOI":"10.1016\/j.diabres.2023.110236","article-title":"Risk factors of dapagliflozin-associated diabetic ketosis\/ketoacidosis in patients with type 2 diabetes mellitus: a matched case-control study","volume":"196","author":"Zhao","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2025102402100662000_32.6.534.11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2019.01.002","article-title":"SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes","volume":"846","author":"Donnan","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"2025102402100662000_32.6.534.12","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4103\/jfmpc.jfmpc_644_21","article-title":"Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: a systematic review and quantitative analysis","volume":"11","author":"Dutta","year":"2022","journal-title":"J Family Med Prim Care"},{"key":"2025102402100662000_32.6.534.13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/14740338.2023.2275704","article-title":"The risk factors of diabetic ketosis and diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors: a retrospective study","volume":"23","author":"Zhao","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"2025102402100662000_32.6.534.14","unstructured":"US Food and Drug Administration . FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. n.d. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious"},{"key":"2025102402100662000_32.6.534.15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/nep.14167","article-title":"Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries: an expert consensus statement","volume":"28","author":"Liew","year":"2023","journal-title":"Nephrology (Carlton)"},{"key":"2025102402100662000_32.6.534.16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40264-022-01247-3","article-title":"A population-based study of SGLT2 inhibitor-associated postoperative diabetic ketoacidosis in patients with type 2 diabetes","volume":"46","author":"Lui","year":"2023","journal-title":"Drug Saf"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:10:33Z","timestamp":1761297033000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,24]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/ejhpharm-2024-004124"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004124","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}